Cargando…

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

PARP inhibitors (PARPi) have activity in homologous recombination (HR) repair-deficient, high-grade serous ovarian cancers (HGSOC). However, even responsive tumors develop PARPi resistance, highlighting the need to delay or prevent the appearance of PARPi resistance. Here, we showed that the ALK kin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanakkanthara, Arun, Hou, Xiaonan, Ekstrom, Thomas L., Zanfagnin, Valentina, Huehls, Amelia M., Kelly, Rebecca L., Ding, Husheng, Larson, Melissa C., Vasmatzis, George, Oberg, Ann L., Kaufmann, Scott H., Mansfield, Aaron S., Weroha, S. John, Karnitz, Larry M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Translational Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770599/ https://www.ncbi.nlm.nih.gov/pubmed/34810199 http://dx.doi.org/10.1158/0008-5472.CAN-21-0732

Ejemplares similares

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
por: Ekstrom, Thomas L., et al.
Publicado: (2021)

ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer
por: Kanakkanthara, Arun, et al.
Publicado: (2019)

Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil
por: Geng, Liyi, et al.
Publicado: (2011)

Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo
por: Vincelette, Nicole D., et al.
Publicado: (2019)

Intra-S phase checkpoint kinase Chk1 dissociates replication proteins Treslin and TopBP1 through multiple mechanisms during replication stress
por: Kelly, Rebecca L., et al.
Publicado: (2022)

Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A
por: Torres, Diogo, et al.
Publicado: (2019)

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
por: Hurley, Rachel M, et al.
Publicado: (2021)

Are PARPs promiscuous?
por: Feijs, Karla L.H., et al.
Publicado: (2022)

Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
por: Mansfield, A. S., et al.
Publicado: (2016)

Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy
por: Schäkel, Laura, et al.
Publicado: (2022)

Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer
por: Huang, Dongqing, et al.
Publicado: (2021)

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
por: Znojek, P, et al.
Publicado: (2014)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
por: Beck, Olaf, et al.
Publicado: (2020)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium
por: Goranova, T, et al.
Publicado: (2017)

MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea
por: McDaid, J R, et al.
Publicado: (2009)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
por: Hotta, Takamasa, et al.
Publicado: (2019)

CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
por: Bronger, Holger, et al.
Publicado: (2016)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases
por: Mekhaeil, Marianna, et al.
Publicado: (2022)

Optimizing Automated Peritoneal Dialysis Using an Extended 3-Pore Model
por: Öberg, Carl M., et al.
Publicado: (2017)

Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts
por: Liu, Yuanhang, et al.
Publicado: (2019)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts()()
por: Butler, Kristina A., et al.
Publicado: (2017)

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
por: Koti, M, et al.
Publicado: (2015)

Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors
por: Cotler, Max J., et al.
Publicado: (2022)

Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018)

Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
por: Harris, Faye R., et al.
Publicado: (2018)

Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer
por: Harrington, Brittney S, et al.
Publicado: (2016)

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
por: Ramos, Louise, et al.
Publicado: (2023)

Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors
por: Rampogu, Shailima, et al.
Publicado: (2023)

Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
por: Liu, Dongyan, et al.
Publicado: (2021)

STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
por: Rüschoff, Jan H., et al.
Publicado: (2019)

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma
por: Cocco, E, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_k8vb9aggrjde4l7knk7k55n0fu